FDA gains power to track device design changes and cleanliness verification

What it does

This bill requires medical device manufacturers to notify the FDA before making changes to device design or reprocessing instructions, and to report within 5 days when they communicate about design changes, reprocessing changes, or safety concerns to foreign healthcare providers. It also establishes a new category of devices called 'rapid assessment tests' used to verify that reusable medical devices are properly cleaned and sterilized, and requires manufacturers to provide validated instructions and data for these tests.

Why we flagged it

The bill's core function is to impose new transparency and reporting obligations on device manufacturers regarding design changes, reprocessing protocols, and foreign communications. This is a regulatory compliance measure, not a deregulation or carve-out.

What the text implies

• The 5-day reporting window for foreign communications may create competitive intelligence disclosure risk if manufacturers must report market-sensitive information about device modifications to competitors operating in the same foreign markets.
• The FDA's discretion to define which rapid assessment tests require validated instructions (Section 4(b)(1)) creates potential for regulatory bottlenecks if the agency moves slowly in publishing the initial list, delaying market access for new cleaning-verification devices.
• Manufacturers may face liability exposure if a device is deemed adulterated solely for failure to report a design change, even if the change itself posed no safety risk — the reporting violation becomes the violation, not the change's substance.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Patients using reusable medical devices (surgical instruments, endoscopes, etc.) benefit from mandatory reporting of design and reprocessing changes, which increases FDA oversight and reduces the risk of harm from improperly cleaned or modified devices. The requirement that manufacturers report communications to foreign providers about safety concerns ensures the FDA is aware of potential safety issues globally, improving domestic patient safety.

Who stands to gain

• Medical device manufacturers (compliance cost offset by reduced liability from proactive reporting)
• Rapid assessment test manufacturers (new market created for cleaning-verification devices)
• FDA (expanded enforcement authority and reporting data)

Named in the bill

FDA (Food and Drug Administration), Medical device manufacturers, Reusable medical device industry, Foreign healthcare providers, Rapid assessment test manufacturers

Where it stands

2 cosponsors: 2 Democrats.

• Mar 26, 2025 — Introduced · Congress.gov: “Introduced in House”
• Mar 26, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.